Clinical Trials Logo

Clinical Trial Summary

The aim of this clinical trial is to investigate the efficacy (by monitoring the wound size reduction) and safety (by monitoring occurring adverse events) of the investigational medicinal product APZ2 after one single application on chronic venous leg ulcer wounds.


Clinical Trial Description

This is an interventional, single arm, phase I/IIa clinical trial to investigate the efficacy and safety of ABCB5+ mesenchymal stem cells (MSCs) on wound healing in patients with chronic venous ulcer (CVU). Autologous MSCs will be isolated ex vivo from a small skin biopsy and will be expanded in vitro. The IMP APZ2 containing the ABCB5+ cells will then be applied on the wound surface of CVU under local anesthesia.

Patients are followed up for efficacy for 3 months which allows to distinguish actual wound healing from transient wound coverage.

The wound healing process will be documented by standardized photography. The wound size evaluation will start on the day of the first change of wound dressing. The quality of the wound healing process will be assessed on the basis of formation of granulation tissue, epithelialization and wound exudation.

Pain will be assessed using a numerical rating scale and quality of life will be investigated with standardized and validated questionnaires. To assess long-term safety of APZ2 an additional follow-up visit at Month 12 post IMP application is included. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02742844
Study type Interventional
Source RHEACELL GmbH & Co. KG
Contact
Status Terminated
Phase Phase 1/Phase 2
Start date August 2016
Completion date January 15, 2019

See also
  Status Clinical Trial Phase
Withdrawn NCT01913704 - Pilot Study Comparing NatroxTM Topical Oxygen Therapy to A Placebo in the Management of Non-Healing Leg Ulcers N/A
Completed NCT03257098 - Allogeneic ABCB5-positive Stem Cells for Treatment of CVU Phase 1/Phase 2
Terminated NCT02307448 - Effectiveness of Autologous Platelet Rich Plasma in the Treatment of Chronic Non-Healing Wounds N/A
Recruiting NCT04971161 - Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of CVU (Phase IIb) Phase 2